MAAT INDEX

CLAIM #3725 · Accenture plc (ACN) · 2024Q4 earnings call · Sep 26, 2024 · due Aug 31, 2025

Well, I think it starts with, we're not seeing a change in what our clients are spending on IT, right? So -- but what we are seeing is the continued trend of trying to save money on IT to free up the spending on areas of GenAI.

Julie Sweet · CEO

PENDING
graded after results covering Aug 31, 2025 are reported

In context

t kind of give some flexibility. We’re not seeing that, right? We sell more of the same this quarter. And so as we kind of go into the year, at the top end of the range, it’s the current environment going forward. And at the bottom of the range, if you were to ask me today, what is that mostly accommodated is if there was a deterioration in spending, right, so -- because of kind of the way we’ve positioned ourselves. Bryan Keane: Great. Thank you. Julie Sweet: Thanks. Operator: We'll go next to the line of Dan Dolev with Mizuho. Dan Dolev: Hi. Thanks for taking my questions. Great results and great guidance here. Two questions on GenAI. Are you seeing more of your conversations being less replacement and reallocation and purely incremental on G&A? And then I have a follow-up. Julie Sweet: Well, I think it starts with, we're not seeing a change in what our clients are spending on IT, right? So -- but what we are seeing is the continued trend of trying to save money on IT to free up the spending on areas of GenAI. So on the one hand, right now, we haven't seen a change in overall spending. We'll see what the budgets come in January, February, but we're not expecting a big change. But what we also are seeing is that as they're saving money, they want to invest it in things like GenAI and data. So that's really the dynamic that's going on, save to invest, but we haven't seen signs of overall change. Dan Dolev: Got it. And then a quick follow-up on margins. Can you maybe touch on the GenAI services margin, how it stands versus your traditional business? I think that would be really helpful for investors. Thank you. Julie Sweet: Are you -- I mean, are GenAI margin and sort of -- is that different from when we're doing GenAI versus other GenAI technology? Dan Dolev: Correct. GenAI services versus your t

Verify independently

SEC filings for ACN · Claim quote is verbatim from the 2024Q4 earnings call.